

TOTAL PRODUCTION

Nom de l'équipe : Immunopathology and therapeutic immuno-intervention

Nom du directeur pour le contrat en cours : Sébastien Lacroix-Desmazes

Nom du directeur pour le contrat à venir : Sébastien Lacroix-Desmazes

I. PRODUITS DE LA RECHERCHE

Publications made in collaboration with other teams of the CRC are flagged with ■

Publications of staff recruited during the last five years and done in their previous team are flagged with ➡

1. Journaux / revues

2017

1. Hadzhieva M, Pashov AD, Kaveri S, Lacroix-Desmazes S, Mouquet H and Dimitrov JD. Impact of Antigen Density on the Binding Mechanism of IgG Antibodies. *Sci Rep* 2017 (in press doi: 10.1038/s41598-017-03942-z)
2. ■ Stephen-Victor E, Das M, Sharma M, Galeotti C, Fohrer-Ting H, Sendid B, Darnige L, Terris B, Badoual C, Bruneval P, Kaveri SV, Bayry J. Demystification of enigma on antigen-presenting cell features of human basophils: data from secondary lymphoid organs. *Haematologica* 2017. 102: e233-e237.
3. Shahsavarian MA, Chaaya N, Costa N, Boquet D, Atkinson A, Offmann B, Kaveri SV, Lacroix-Desmazes S, Friboulet A, Avelle B, Padiolleau-Lefevre S. Multitarget selection of catalytic antibodies with beta-lactamase activity using phage display. *FEBS J.* 2017. 284: 634-653.
4. Saha C, Das M, Patil V, Stephen-Victor E, Sharma M, Wymann S, Jordi M, Vonarburg C, Kaveri SV, Bayry J. Monomeric Immunoglobulin A from Plasma Inhibits Human Th17 Responses In Vitro Independent of FcαRI and DC-SIGN. *Front Immunol.* 2017. 8: Article number 275.
5. Maddur MS, Stephen-Victor E, Das M, Prakhar P, Sharma VK, Singh V, Rabin M, Trinath J, Balaji KN, Bolgert F, Vallat JM, Magy L, Kaveri SV, Bayry J. Regulatory T cell frequency, but not plasma IL-33 levels, represents potential immunological biomarker to predict clinical response to intravenous immunoglobulin therapy. *J Neuroinflammation* 2017. 14: Article number 58.
6. Klein A, Sagi-Assif O, Meshel T, Telerman A, Izraely S, Ben-Menachem S, Bayry J, Marzese DM, Ohe S, Hoon DSB, Erez N, Witz IP. CCR4 is a determinant of melanoma brain metastasis. *Oncotarget* 2017. 8: 31079-31091.
7. Gangadharan B, Ing M, Delignat S, Peyron I, Teyssandier M, Kaveri SV, Lacroix-Desmazes S. The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells. *Haematologica* 2017. 102: 271-281.
8. ■ Djoumerska-Alexieva I, Roumenina LT, Stefanova T, Vassilev T, Dimitrov JD. Heme-Exposed Pooled Therapeutic IgG Improves Endotoxemia Survival. *Inflammation* 2017. 40: 117-122.
9. Davies MN, Pere H, Bosschem I, Haesebrouck F, Flahou B, Tartour E, Flower DR, Tough DF, Bayry J. In Silico Adjuvant Design and Validation. *Methods Mol Biol.* 2017. 1494: 107-125.
10. Das M, Galeotti C, Stephen-Victor E, Karnam A, Kaveri SV, Bayry J. Human basophils may not undergo modulation by DC-SIGN and mannose receptor-targeting immunotherapies due to absence of receptors. *J Allergy Clin Immunol.* 2017. 139: 1403-1404 e1401.
11. ■ Djoumerska-Alexieva I, Roumenina L, Pashov A, Dimitrov J, Hadzhieva M, Lindig S, Voynova E, Dimitrova P, Ivanovska N, Bockmeyer C, Stefanova Z, Fitting C, Bläss M, Claus R, Von Gunten S, Kaveri S, Cavailon JM, Bauer M, Vassilev T. Intravenous Immunoglobulin with Enhanced Polyspecificity Improves Survival in Experimental Sepsis and Aseptic Systemic Inflammatory Response Syndromes. *Mol Med.* 2017. doi: 10.2119/molmed.2014.00224. (Epub ahead of print)

2016

12. Mahendra A, Peyron I, Thauinat O, Dollinger C, Gilardin L, Sharma M, Wootla B, Rao DN, Padiolleau-Lefevre S, Boquet D, More A, Varadarajan N, Kaveri SV, Legendre C, Lacroix-Desmazes S. Generation of Catalytic Antibodies Is an Intrinsic Property of an Individual's Immune System: A Study on a Large Cohort of Renal Transplant Patients. *J Immunol.* 2016. 196: 4075-4081.
13. Galeotti C, Hegde P, Das M, Stephen-Victor E, Canale F, Munoz M, Sharma VK, Dimitrov JD, Kaveri SV, Bayry J. Heme oxygenase-1 is dispensable for the anti-inflammatory activity of intravenous immunoglobulin. *Sci Rep.* 2016. 6: Article number 19592.

14. Stephen-Victor E, Sharma VK, Das M, Karnam A, Saha C, Lecerf M, Galeotti C, Kaveri SV, Bayry J. IL-1beta, But Not Programed Death-1 and Programed Death Ligand Pathway, Is Critical for the Human Th17 Response to Mycobacterium tuberculosis. *Front Immunol.* 2016. 7: Article number 465.
15. Pinto P, Shetty S, Lacroix-Desmazes S, Bayry J, Kaveri S, Ghosh K. Antibody profile in Indian severe haemophilia A patients with and without FVIII inhibitors. *Immunol Lett* 2016. 169: 93-97.
16. Holla S, Stephen-Victor E, Prakhar P, Sharma M, Saha C, Udupa V, Kaveri SV, Bayry J, Balaji KN. Mycobacteria-responsive sonic hedgehog signaling mediates programmed death-ligand 1- and prostaglandin E2-induced regulatory T cell expansion. *Sci Rep.* 2016. 6: Article number 24193.
17. Kaveri SV, Lacroix-Desmazes S, von Gunten S and Bayry J. Plasma derived and recombinant human plasma proteins (Section 7.2. page 176-178). In: *The European Hematology Association Roadmap for European Hematology Research: A Consensus Document.* Engert A et al. *Haematologica* 2016. 101:115-208.
18. Hadzhieva M, Vassilev T, Bayry J, Kaveri S, Lacroix-Desmazes S, Dimitrov JD. Relationship between natural and heme-mediated antibody polyreactivity. *Biochem Biophys Res Commun.* 2016. 472: 281-286.
19. Beziaud L, Mansi L, Ravel P, Marie-Joseph EL, Laheurte C, Rangan L, Bonnefoy F, Pallandre JR, Boullerot L, Gamonet C, Vrecko S, Queiroz L, Maurina T, Mouillet G, Hon TN, Curtit E, Royer B, Gaugler B, Bayry J, Tartour E, Thiery-Vuillemin A, Pivot X, Borg C, Godet Y, and Adotevi O. Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity. *Cancer Res.* 2016. 76: 4100-4112.
20. Ahmed AR, Shetty S, Kaveri S, Spigelman ZS. Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: A retrospective study with a 6-year follow-up. *J Am Acad Dermatol.* 2016. 74: 700-708 e703.
21. Ahmed AR, Nguyen T, Kaveri S, Spigelman ZS. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up. *Int Immunopharmacol.* 2016. 34: 25-31.
22. Saha C, Das M, Stephen-Victor E, Friboulet A, Bayry J, Kaveri SV. Differential Effects of *Viscum album* Preparations on the Maturation and Activation of Human Dendritic Cells and CD4(+) T Cell Responses. *Molecules* 2016. 21: Article number 912
23. Pradhan V, Pandit P, Rajadhyaksha A, Patwardhan M, Surve P, Kamble P, Lecerf M, Bayry J, Kaveri S, Ghosh K, and Nadkar MY. Association of Serum Ferritin Levels with Hematological Manifestations in Systemic Lupus Erythematosus Patients from Western India. *J Assoc Physicians India* 2016. 64: 14-18.
24. Kreuz W, Escuriola Ettingshausen C, Vdovin V, Zozulya N, Plyushch O, Svirin P, Andreeva T, Bubanská E, Campos M, Benedik-Dolničar M, Jiménez-Yuste V, Kitanovski L, Klukowska A, Momot A, Osmulskaya N, Prieto M, Šalek SZ, Velasco F, Pavlova A, Oldenburg J, Knaub S, Jansen M, Belyanskaya L, Walter O; ObsITI study group.; ObsITI committee. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study. *Haemophilia* 2016. 22:87-95.

2015

25. Gupta N, Culina S, Meslier Y, Dimitrov J, Arnoult C, Delignat S, Gangadharan B, Lecerf M, Justesen S, Gouilleux-Gruart V, Salomon BL, Scott DW, Kaveri SV, Mallone R, Lacroix-Desmazes S. Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance. *Sci Transl Med.* 2015. 7:275ra21. doi: 10.1126/scitranslmed.aaa1957.
26. Gupta N, de Wispelaere M, Lecerf M, Kalia M, Scheel T, Vrati S, Berek C, Kaveri SV, Desprès P, Lacroix-Desmazes S, Dimitrov JD. Neutralization of Japanese Encephalitis Virus by heme-induced broadly reactive human monoclonal antibody. *Sci Rep.* 2015. 5: Article number 16248.
27. Maddur MS, Trinath J, Rabin M, Bolgert F, Guy M, Vallat JM, Magy L, Balaji KN, Kaveri SV and Bayry J. Intravenous immunoglobulin-mediated expansion of regulatory T cells in autoimmune patients is associated with increased prostaglandin E2 levels in the circulation. *Cell Mol Immunol.* 2015. 12:650-652.
28. Lecerf M, Scheel T, Pashov AD, Jarossay A, Ohayon D, Planchais C, Mesnage S, Berek C, Kaveri SV, Lacroix-Desmazes S, Dimitrov JD. Prevalence and gene characteristics of antibodies with cofactor-induced HIV-1 specificity. *J Biol Chem.* 2015. 290:5203-5213.
29. Culina S, Gupta N, Boisgard R, Afonso G, Gagnerault MC, Dimitrov J, Østerbye T, Justesen S, Luce S, Attias M, Kyewski B, Buus S, Wong FS, Lacroix-Desmazes S, Mallone R. Materno-Fetal Transfer of Preproinsulin Through the Neonatal Fc Receptor Prevents Autoimmune Diabetes. *Diabetes* 2015. 64:3532-3542
30. Ahmed AR, Kaveri S, Spigelman Z. Long-Term Remissions in Recalcitrant Pemphigus Vulgaris. *N Engl J Med.* 2015. 373:2693-2694.
31. ■ Vasilev VV, Noe R, Dragon-Durey MA, Chauvet S, Lazarov VJ, Deliyska BP, Fremeaux-Bacchi V, Dimitrov JD, Roumenina LT. Functional Characterization of Autoantibodies against Complement Component C3 in Patients with Lupus Nephritis. *J Biol Chem.* 2015. 290:25343-25355.
32. ■ Hadzhieva M, Vassilev TL, Roumenina L, Bayry J, Kaveri SV, Lacroix-Desmazes S, Dimitrov JD. Mechanism and functional implications of heme-induced binding promiscuity of IgE. *Biochemistry* 2015. 54:2061-2072.
33. Stephen-Victor E, Saha C, Sharma M, Holla S, Balaji KN, Kaveri SV, Bayry J. Inhibition of programmed death 1 ligand 1 on dendritic cells enhances *Mycobacterium*-mediated interferon γ (IFN- γ) production without modulating the frequencies of IFN- γ -producing CD4⁺ T cells. *J Infect Dis.* 2015. 211:1027-1029.
34. Sharma M, Stephen-Victor E, Poncet P, Kaveri SV and Bayry J. Basophils are inept at promoting human Th17 responses. *Hum Immunol.* 2015. 76:176-180.

35. Peyron I, Dimitrov JD, Delignat S, Gangadharan B, Planchais C, Kaveri SV, Lacroix-Desmazes S. Haemarthrosis and arthropathy do not favour the development of factor VIII inhibitors in severe haemophilia A mice. *Haemophilia*. 2015. 21:e94-98
36. Saha C, Hegde P, Friboulet A, Bayry J, Kaveri SV. Viscum album-mediated COX-2 inhibition implicates destabilization of COX-2 mRNA. *PLoS ONE* 2015. 10: Article number e0114965.
37. Bosscem I, Bayry J, De Bruyne E, Van Deun K, Smet A, Vercauteren G, Pasmans F, Ducatelle R, Haesebrouck, Flahou B. Effect of different adjuvants on protection and side-effects induced by *Helicobacter suis* whole-cell lysate vaccination. *PLoS ONE* 2015. 10: Article number e0131364.
38. Hoseini-Alfatemi SM, Bayry J, Sharifi-Rad J. IgE response to two new allergen proteins of *Solanum melongena* L. (eggplant). *Immunol Lett*. 2015. 168:268-270.
39. Brito-Zerón P, Gheitasi H, Retamozo S, Bové A, Londoño M, Sánchez-Tapias JM, Caballero M, Kostov B, Fornis X, Kaveri SV, Ramos-Casals M. How hepatitis C virus modifies the immunological profile of Sjögren syndrome: analysis of 783 patients. *Arthritis Res Ther*. 2015. 17:Article number 250.
40. Stepanov AV, Belogurov AA Jr, Kothapalli P, Shamborant OG, Knorre VD, Telegin GB, Ovsepyan AA, Ponomarenko NA, Deyev SM, Kaveri SV, Gabibov AG. Specific Depletion of Myelin-Reactive B Cells via BCR-Targeting. *Acta Naturae* 2015. 7:74-79.

2014

41. Maddur MS, Sharma M, Hegde P, Stephen-Victor E, Pulendran B, Kaveri SV, Bayry J. Human B cells induce dendritic cell maturation and favour Th2 polarization by inducing OX-40 ligand. *Nature Commun*. 2014. 5: Article number 4092.
42. ■ Rayes J, Roumenina LT, Dimitrov JD, Repessé Y, Ing M, Christophe O, Jokiranta TS, Halbwachs-Mecarelli L, Borel-Derlon A, Kaveri SV, Frémeaux-Bacchi V, Lacroix-Desmazes S. The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. *Blood* 2014.123:121-125.
43. Gangadharan B, Delignat S, Ollivier V, Gupta N, Mackman N, Kaveri SV, Lacroix-Desmazes S. Role of coagulation-associated processes on factor VIII immunogenicity in a mouse model of severe hemophilia A. *J Thromb Haemost*. 2014. 12:2065-2069.
44. Sharma M, Schoindre Y, Hegde P, Saha C, Maddur MS, Stephen-Victor E, Gilardin L, Lecerf M, Bruneval P, Mouthon L, Benveniste O, Kaveri SV, Bayry J. Intravenous immunoglobulin-induced IL-33 is insufficient to mediate basophil expansion in autoimmune patients. *Sci Rep*. 2014. 4: Article number 5672.
45. Othy S, Topçu S, Saha C, Kothapalli P, Lacroix-Desmazes S, Käsermann F, Miescher S, Bayry J, Kaveri SV. Sialylation may be dispensable for reciprocal modulation of helper T lymphocytes by intravenous immunoglobulin in experimental autoimmune encephalomyelitis. *Eur J Immunol*. 2014. 44:2059-2063.
46. Bayry J, Beaussart A, Dufrière Y, Sharma M, Bansal K, Kniemeyer O, Aïmanianda V, Brakhage A, Kaveri SV, Kwon-Chung KJ, Latgé JP, Beauvais A. Surface structure characterization of *Aspergillus fumigatus* conidia mutated in the melanin synthesis pathway and their human cellular immune response. *Infect Immun*. 2014. 82:3141-3153.
47. Dimitrov JD, Planchais C, Scheel T, Ohayon D, Mesnage S, Berek C, Kaveri SV, Lacroix-Desmazes S. A cryptic polyreactive antibody recognizes distinct clades of HIV-1 glycoprotein 120 by an identical binding mechanism. *J Biol Chem*. 2014. 289:17767-17779.
48. Gupta N, Hegde P, Lecerf M, Nain M, Kalia M, Vrati S, Bayry J, Lacroix-Desmazes S, Kaveri SV. Japanese encephalitis virus expands regulatory T cells by increasing the expression of PD-L1 on dendritic cells. *Eur J Immunol*. 2014. 44:1363-1374.
49. Mesnage S, Dellarole M, Baxter NJ, Rouget JB, Dimitrov JD, Wang N, Fujimoto Y, Hounslow AM, Lacroix-Desmazes S, Fukase K, Foster SJ, Williamson MP. Molecular basis for bacterial peptidoglycan recognition by LysM domains. *Nat Commun*. 2014. 5: Article number 4269.
50. Sharma M, Lecerf M, Friboulet A, Kaveri SV, Dissous C, Bayry J. Mediation of T-helper 17 responses to schistosomes by dendritic cells but not basophils. *J Infect Dis*. 2014. 209:2019-2021.
51. Holla S, Sharma M, Vani J, Kaveri SV, Balaji KN, Bayry J. GM-CSF along with IL-4 but not alone is indispensable for the differentiation of human dendritic cells from monocytes. *J Allergy Clin Immunol* 2014. 133:1500-1502.e1.
52. Holla S, Kurowska-Stolarska M, Bayry J, Balaji KN. Selective inhibition of IFNG-induced autophagy by MIR155 and MIR31-responsive WNT5A and SHH signaling. *Autophagy* 2014. 10:311-330.
53. Maddur MS, Rabin M, Hegde P, Bolgert F, Guy M, Vallat JM, Magy L, Bayry J, Kaveri SV. 2014. Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barré syndrome patients. *Immunol Res*. 60:320-329
54. ■ Bouhlal H, MartINVALLET D, Teillaud JL, Fridman CS, Kazatchkine MD, Bayry J, Lacroix-Desmazes S, Kaveri SV. Natural autoantibodies to Fcγ receptors in intravenous immunoglobulins. *J Clin Immunol*. 2014. 34:S4-S11.
55. Mahendra A, Gangadharan B, André S, Boudjoghra M, Davi F, Lecerf M, Planchais C, Kaveri SV, Lacroix-Desmazes S, Dimitrov JD. Cryptic polyreactivity of IgG expressed by splenic marginal zone B-cell lymphoma. *Mol Immunol*. 2014. 60:54-61.
56. Casulli S, Coignard H, Amazzough K, Shoai-Tehrani M, Bayry J, Mahlaoui N, Elbim C, Kaveri SV. Defective functions of polymorphonuclear neutrophils in patients with common variable immunodeficiency. *Immunol Res*. 2014. 60:69-76.

57. Delignat S, Repessé Y, Gilardin L, Dimitrov JD, Lone YC, Kaveri SV, Lacroix-Desmazes S. 2014. Predictive immunogenicity of Refacto AF. *Haemophilia* 20:486-492.
58. Pashov AD, Calvez T, Gilardin L, Maillère B, Repessé Y, Oldenburg J, Pavlova A, Kaveri SV, Lacroix-Desmazes S. In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene. *Haemophilia*. 2014. 20:176-184.
59. ■ Dalmas E, Venteclef N, Caer C, Poitou C, Cremer I, Aron-Winewsky J, Lacroix-Desmazes S, Bayry J, Kaveri SV, Clément K, André S, Guerre-Millo M. T cell-derived IL-22 amplifies IL-1 β -driven inflammation in human adipose tissue: relevance to obesity and type 2 diabetes. *Diabetes* 2014. 63:1966-1977.
60. Elluru SR, Kaveri SV, Bayry J. Regulation of human dendritic cell functions by natural anti-CD40 antibodies. *Methods Mol Biol.* 2014. 1155: 47-54.
61. Shahsavarian MA, Le Minoux D, Matti KM, Kaveri S, Lacroix-Desmazes S, Boquet D, Friboulet A, Avelle B, Padiolleau-Lefèvre S. Exploitation of rolling circle amplification for the construction of large phage-display antibody libraries. *J Immunol Methods.* 2014. 407:26-34
62. Patil PK, Sajjanar CM, Natarajan C, Bayry J. Neutralizing antibody responses to foot-and-mouth disease quadrivalent (type O, A, C and Asia 1) vaccines in growing calves with pre-existing maternal antibodies. *Vet Microbiol.* 2014. 169:233-235.
63. Djoumerska-Alexieva I, Manoylov I, Dimitrov JD, Tchorbanov A. Serum or breast milk immunoglobulins mask the self-reactivity of human natural IgG antibodies. *APMIS* 2014. 122:329-340.
64. Pradhan V, Nadkar Milind, Rajadhyaksha A, Pandit P, Surve P, Lecerf M, Bayry J, Kaveri SV, Gosh K. Clinical and autoimmune profile of Scleroderma patients from Western India. *Int J Rheumatol.* 2014: Article number 983781.

2013

65. Trinath J, Hegde P, Sharma M, Maddur MS, Rabin M, Vallat JM, Magy L, Balaji KN, Kaveri SV, Bayry J. Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells. *Blood* 2013. 122:1419-1427.
66. Othy S, Hegde P, Topçu S, Sharma M, Maddur MS, Lacroix-Desmazes S, Bayry J, Kaveri SV. Intravenous gammaglobulin inhibits encephalitogenic potential of pathogenic T cells and interferes with their trafficking to central nervous system implicating sphingosine-1 phosphate receptor 1-mammalian target of rapamycin axis. *J Immunol.* 2013. 190:4535-4541.
67. Repressé Y, Peyron I, Dimitrov JD, Dasgupta S, Moshai EF, Costa C, Borel-Derlon A, Guillet B, D'Oiron R, Aouba A, Rothschild C, Oldenburg J, Pavlova A, Kaveri SV, Lacroix-Desmazes S; ABIRISK consortium. Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter. *Haematologica.* 2013. 98:1650-1655.
68. Sharma M, Hegde P, Aimananda V, Beau R, Maddur MS, Sénéchal H, Poncet P, Latgé JP, Kaveri S, Bayry J. Circulating human basophils lack the features of professional antigen presenting cells. *Sci Rep.* 2013.3: Article number 1188.
69. Maddur MS, Sharma M, Hegde P, Lacroix-Desmazes S, Kaveri SV, Bayry J. Inhibitory effect of IVIG on IL-17 production by Th17 cells is independent of anti-IL-17 antibodies in the immunoglobulin preparations. *J Clin Immunol.* 2013. 33: 562-566.
70. Vani J, Shaila, MS, Trinath J, Balaji KN, Kaveri SV, Bayry J. *Mycobacterium tuberculosis* cell wall-associated Rv3812 protein induces strong dendritic cell-mediated interferon γ responses and exhibits vaccine potential. *J Infect Dis.* 2013. 208:1034-1036.
71. Trinath J, Hegde P, Balaji KN, Kaveri SV, Bayry J. Intravenous immunoglobulin-mediated regulation of notch ligands on human dendritic cells. *J Allergy Clin Immunol.* 2013. 131:1255-1257, 1257.e1.
72. Gupta N, LeGoff J, Chamat S, Mercier-Delarue S, Touzelet O, Power UF, Kazatchkine MD, Simon F, Lacroix-Desmazes S, Bayry J, Kaveri SV. Affinity-purified respiratory syncytial virus antibodies from intravenous immunoglobulin exert potent antibody-dependent cellular cytotoxicity. *PLoS ONE* 2013. 8: Article number e69390.
73. Mahendra A, Peyron I, Dollinger C, Gilardin L, Sharma M, Wootla B, Padiolleau-Lefevre S, Friboulet A, Boquet D, Legendre C, Kaveri SV, Thaunat O, Lacroix-Desmazes S. IVIg treatment reduces catalytic antibody titers of renal transplanted patients. *PLoS One.* 2013. 8: Article number e70731.
74. Sharma M, Kaveri SV, Bayry J. Human basophils lack the capacity to drive memory CD4⁺ T cells toward the IL-22 response. *J Allergy Clin Immunol.* 2013. 132:1457-1458, 1458.e1.
75. Dimitrov JD, Kaveri SV, Lacroix-Desmazes S. Gain of function of immunoglobulins after partial unfolding or cofactor binding. *Mol Immunol.* 2013. 55:195-196.
76. Teyssandier M, André S, Gupta N, Dasgupta S, Bayry J, Kaveri SV, Lacroix-Desmazes S; ABRISK consortium. Therapeutic factor VIII does not trigger TLR1.2 and TLR2.6 signalling *in vitro*. *Haemophilia.* 2013. 19:399-402.
77. ■ Frimat M, Tabarin F, Dimitrov JD, Poitou C, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT. Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. *Blood* 2013. 122:282-292.
78. Shevchenko I, Karakhanova S, Soltek S, Link J, Bayry J, Werner J, Umansky V, Bazhin A. Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. *Int J Cancer* 2013. 133:98-107.
79. Ghorpade DS, Holla S, Kaveri SV, Bayry J, Patil SA, Balaji KN. Sonic hedgehog-dependent induction of microRNA-31 and microRNA-150 regulates *M. bovis* BCG-driven TLR2 signaling. *Mol Cell Biol.* 2013. 33:543-556.

80. Bonduelle O, Yahia N, Siberil S, Benhabiles N, Carrat F, Krivine A, Rozenberg F, Dimitrov J, Kaveri SV, Curjol A, Tindel M, Louet M, Desert F, Launay O, Loulergue P, Badre G, Katlama C, Bricaire F, Samri A, Rousset D, van der Werf S, Jauréguiberry S and Combadiere B. Longitudinal and integrative biomodeling of effector and memory immune compartments after inactivated influenza vaccination. *J Immunol.* 2013. 191:623-631.
81. Alsteens D, Aïmanianda V, Hegde P, Pire S, Beau R, Bayry J, Latgé JP, Dufrêne YF. Unravelling the nanoscale surface properties of chitin synthase mutants of *Aspergillus fumigatus* and their biological implications. *Biophys J.* 2013. 105: 320-327.
82. Hausammann S, Vogel M, Kremer Hovinga JA, Lacroix-Desmazes S, Stadler BM and Horn MP. Designed ankyrin repeat proteins: a new approach to mimic complex antigens for diagnostic purposes? *PLoS One.* 2013. 8: Article number e60688.

2012

83. Repešé Y, Dimitrov JD, Peyron I, Farrokhi Moshai E, Kiger L, Dasgupta S, Delignat S, Marden MC, Kaveri SV, Lacroix-Desmazes S. Heme binds to factor VIII and inhibits its interaction with activated factor IX. *J Thromb Haemost.* 2012. 10:1062-1071.
84. ■ Othy S, Bruneval P, Topçu S, Dugail I, Delers F, Lacroix-Desmazes, Bayry J, Kaveri SV. Effect of IVIg on human dendritic cell-mediated antigen uptake and presentation: role of lipid accumulation. *J Autoimmun.* 2012. 39: 168-172.
85. Maddur MS, Kaveri SV, Bayry J. Regulation of human dendritic cells by B cells depends on the signals they receive. *Blood* 2012. 119:3863-3864.
86. Dimitrov JD, Christophe OD, Kang J, Repešé Y, Delignat S, Kaveri SV, Lacroix-Desmazes S. Thermodynamic analysis of the interaction of factor VIII with von Willebrand factor. *Biochemistry* 2012. 51:4108-4116.
87. Repešé Y, Dasgupta S, Navarrete AM, Delignat S, Kaveri SV, Lacroix-Desmazes S. Mannose-sensitive receptors mediate the uptake of factor VIII therapeutics by human dendritic cells. *J Allergy Clin Immunol.* 2012. 129:1172-1173.
88. Othy S, Topçu S, Kaveri SV, Bayry J. Effect of CC chemokine receptor 4 antagonism on the evolution of experimental autoimmune encephalomyelitis. *Proc Natl Acad Sci. USA.* 2012. 109:E2412-E2413.
89. Bayry J, Mouthon L, Kaveri SV. Intravenous immunoglobulin expands regulatory T cells in autoimmune rheumatic disease. *J Rheumatol.* 2012. 39:450-451.
90. Trinath J, Maddur MS, Kaveri SV, Balaji KN, Bayry J. *Mycobacterium tuberculosis* promotes regulatory T-cell expansion via induction of programmed death-1 ligand 1 (PD-L1, CD274) on dendritic cells. *J Infect Dis.* 2012. 205:694-696
91. Delignat S, Repešé Y, Navarrete AM, Meslier Y, Gupta N, Christophe OD, Kaveri SV, Lacroix-Desmazes S. Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A. *Haemophilia* 2012. 18:248-254
92. Teyssandier M, Delignat S, Rayes J, Bryckaert M, Jandrot-Perrus M, Kaveri SV, Lacroix-Desmazes S. Activation state of platelets in experimental severe hemophilia A. *Haematologica* 2012. 97:1115-1116.
93. Le Minoux D, Mahendra A, Kaveri S, Limnios N, Friboulet A, Avalle B, Boquet D, Lacroix-Desmazes S, Padiolleau-Lefèvre S. A novel molecular analysis of genes encoding catalytic antibodies. *Mol Immunol.* 2012. 50:160-168.
94. Vitali C, Mingozzi F, Broggi A, Barresi S, Zolezzi F, Bayry J, Raimondi G, Zanoni I, Granucci F. Migratory and not lymphoid-resident dendritic cells maintain peripheral self-tolerance and prevent autoimmunity via induction of iTreg cells. *Blood* 2012. 120:1237-1245.
95. Vani J, Kaveri SV, Bayry J. Myeloid dendritic cell dysfunction during primary HIV-1 infection is independent of interaction with gp120. *J Infect Dis.* 2012. 205:1893-1895.
96. Hegde P, Kaveri SV, Bayry J. Toll-like receptor-2 ligand lipomannan from *Mycobacterium tuberculosis* does not stimulate inflammatory cytokines in dendritic cells. *AIDS* 2012. 26:1182-1184
97. Vani J, Sharma M, Shaila MS, Kaveri SV, Bayry J. Impact of gp120 on dendritic cell-derived chemokines: relevance for the efficacy of gp120-based vaccines for HIV-1. *Clin Vaccine Immunol.* 2012. 19:1335-1336.
98. Viqar B, Gopinath A, Dimitrov JD, Kang J. Comment on Enhancement of the catalytic activity of a 27 kDa subtilisin-like enzyme from *Bacillus amyloliquefaciens* CH51 by in vitro mutagenesis. *J Agric Food Chem.* 2012. 60:4170-4172.
99. Fornasa G, Clement M, Groyer E, Gaston AT, Khallou-Laschet J, Morvan M, Guedj K, Kaveri SV, Tedgui A, Michel JB, Nicoletti A, Caligiuri G. A CD31-derived peptide prevents angiotensin II-induced atherosclerosis progression and aneurysm formation. *Cardiovasc Res.* 2012. 94: 30-37.

Articles de synthèse / revues bibliographiques

2017

1. Stephen-Victor E, Bosschem I, Haesebrouck F, Bayry J. The Yin and Yang of regulatory T cells in infectious diseases and avenues to target them. *Cell Microbiol.* 2017. 19: Article number e12746.

2016

2. Bayry J. Repressing immunity in autoimmune disease. *N Engl J Med.* 2016. 374:2090-2092.

3. ■ Bayry J, Gautier JF. Regulatory T cell immunotherapy for type 1 diabetes: a step closer success? *Cell Metab.* 2016. 23:231-233.
4. Shopsis B, Kaveri SV, Bayry J. Tackling difficult *Staphylococcus aureus* infections: Antibodies show the way. *Cell Host & Microbe* 2016. 20:555-557.
5. Lacroix-Desmazes S, Maillere B. Monoepitopic anti-FVIII T-cell response. *Blood* 2016. 128:1999-2001.
6. Bayry J. Lupus pathogenesis: role of IgE autoantibodies. *Cell Res.* 2016. 26:271-272.
7. ■ Roumenina LT, Rayes J and Lacroix-Desmazes S, Dimitrov JD. Heme: Modulator of Plasma Systems in Hemolytic Diseases. *Trends Mol Med.* 2016. 22:200-213.
8. Stephen-Victor E, Fickenscher H, Bayry J. IL-26: an emerging proinflammatory member of the IL-10 cytokine family with multifaceted actions in antiviral, antimicrobial and autoimmune responses. *PLoS Pathog.* 2016. 12: Article number e1005624.
9. Galeotti C, Kaveri SV, Cimaz R, Koné-Paut I, Bayry J. Predisposing factors, pathogenesis and therapeutic intervention of Kawasaki disease. *Drug Discov Today* 2016. 21:1850-1857.
10. Goudemand J, Peyvandi F, Lacroix-Desmazes S. Key insights to understand the immunogenicity of FVIII products. *Thromb Haemost.* 2016. 116 Suppl 1:S2-9.
11. Kohler H, Bayry J, Kaveri SV. The homophilic domain-an immunological archetype. *Front Immunol.* 2016. 7: Article number 106.
12. Sharma V, Kaveri SV, Bayry J. Impaired regulatory T cell function in autoimmune diseases: are microRNAs the culprits? *Cell Mol Immunol.* 2016. 13:135-137.
13. Batsuli G, Meeks SL, Herzog RW, Lacroix-Desmazes S. Innovating immune tolerance induction for haemophilia. *Haemophilia* 2016. 22 Suppl 5:31-5.
14. Ing M, Gupta N, Teyssandier M, Maillère B, Pallardy M, Delignat S, Lacroix-Desmazes S; ABIRISK consortium. Immunogenicity of long-lasting recombinant factor VIII products. *Cell Immunol.* 2016. 301:40-48.
15. Bontempi I, Vicco MH, Bayry J. Chronic Chagas disease: can prophylaxis and therapeutic vaccines crack this 'hard nut'? *Immunotherapy* 2016. 8:99-101.
16. Singh BN, Saha C, Galun D, Upreti DK, Bayry J, Kaveri SV. European *Viscum album*: a potent phytotherapeutic agent with multifarious phytochemicals, pharmacological properties and clinical evidence. *RSC Adv.* 2016. 6:23837-23857.

2015

17. Sharma M, Bayry J. Autoimmunity: Basophils in autoimmune and inflammatory diseases. *Nature Rev Rheumatol.* 2015. 11:129-131.
18. Galeotti C, Kaveri SV, Bayry J. Molecular and immunological biomarkers to predict IVIg response. *Trends Mol Med.* 2015. 21:145-147.
19. Bayry J, Hartung HP, Kaveri SV. IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties. *Trends Pharmacol Sci.* 2015. 36:419-421.
20. Gilardin L, Bayry J, Kaveri SV. Intravenous immunoglobulin as clinical immune-modulating therapy. *CMAJ* 2015. 187:257-264.
21. Elluru SR, Kaveri SV, Bayry J. The protective role of immunoglobulins in fungal infections and inflammation. *Semin Immunopathol.* 2015. 37:187-197.
22. Oldenburg J, Lacroix-Desmazes S, Lillicrap D. Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity. *Haematologica* 2015. 100:149-156.
23. Maddur MS, Bayry J. B cells drive Th2 responses by instructing human dendritic cell maturation. *Oncoimmunology* 2015. 4: Article number e1005508.
24. Das M, Kaveri SV, Bayry J. Cross-presentation of antigens by dendritic cells: role of autophagy. *Oncotarget* 2015. 6:28527-28528.
25. Jarossay A, Hadzhieva M, Kaveri SV, Lacroix-Desmazes S, Dimitrov JD. Natural and Induced Antibody Polyreactivity. *Anticancer Agents Med Chem.* 2015. 15:1230-1241.

2014

26. Dimitrov JD, Kaveri SV, Lacroix-Desmazes S. Thermodynamic stability contributes to immunoglobulin specificity. *Trends Biochem Sci.* 2014. 39:221-226.
27. Bayry J*, Tartour E, Tough DF. Targeting CCR4 as an emerging strategy for cancer therapy and vaccines. *Trends Pharmacol Sci.* 2014. 35:163-165.
28. Bayry J. Regulatory T cells as adjuvant target for enhancing the viral disease vaccine efficacy. *Virusdisease* 2014. 25:18-25.

2013

29. Buttman M, Kaveri S, Hartung HP. Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disorders. *Trends Pharmacol Sci.* 2013. 34: 445-457.
30. ■ Dimitrov JD, Planchais C, Roumenina LT, Vassilev TL, Kaveri SV, Lacroix-Desmazes S. Antibody polyreactivity in health and disease: statu variabilis. *J Immunol.* 2013. 191:993-999.

31. Sharma M, Kaveri SV, Bayry J. Th17 cells, pathogenic or not? TGF- β 3 imposes the embargo. *Cell Mol Immunol*. 2013. 10: 101-102.
32. Mahendra A, Sharma M, Rao DN, Peyron I, Planchais C, Dimitrov JD, Kaveri SV, Lacroix-Desmazes S. Antibody-mediated catalysis: induction and therapeutic relevance. *Autoimmun Rev*. 2013. 12:648-652.
33. Bazhin A, Bayry J, Umansky V, Werner J, Karakhanova S. Overcoming immunosuppression as a new immunotherapeutic approach against pancreatic cancer. *Oncoimmunology* 2013. 2: Article number e25736.
34. Bayry J. Emerging viral diseases of livestock in the developing world. *Indian J Virol*. 2013. 24: 291-294.
35. Planchais C, Gupta N, Kaveri SV, Lacroix-Desmazes S, Dimitrov JD. [Post-translational diversification of immunoglobulins specificity]. *Med Sci (Paris)*. 2013. 29: 937-940.

2012

36. Maddur MS, Miossec P, Kaveri SV, Bayry J. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. *Am J Pathol*. 2012. 181:8-18.
37. Kaveri S, Silverman GJ, Bayry J. Natural IgM in immune equilibrium and harnessing their therapeutic potential. *J Immunol*. 2012. 188:939-945.
38. Bayry J, Aïmanianda V, Guijarro JI, Sunde M, Latgé JP. Hydrophobins-unique fungal proteins. *PLoS Pathog*. 2012. 8: Article number e1002700.
39. Mahendra A, Padiolleau-Lefevre S, Kaveri SV, Lacroix-Desmazes S. Do proteolytic antibodies complete the panoply of the autoimmune response in acquired haemophilia A? *Br J Haematol*. 2012. 156:3-12.
40. Kaveri SV. Intravenous immunoglobulin: exploiting the potential of natural antibodies. *Autoimmun Rev*. 2012. 11:792-794.
41. Bayry J. Chemokine axis as a therapeutic target to enhance the recruitment of Tregs and treat organ-specific autoimmune and inflammatory diseases. *Immunotherapy* 2012. 4: 9-12.
42. Dimitrov JD, Pashov AD, Vassilev TL. Antibody polyspecificity: what does it matter? *Adv Exp Med Biol*. 2012. 750:213-26.
43. Bouhlal H, Kaveri S. Multi-faceted role of naturally occurring autoantibodies in fighting pathogens. *Adv Exp Med Biol* 2012. 750: 100-113.
44. ■ Pere H, Tanchot C, Bayry J, Terme M, Taieb J, Badoual C, Adotevi O, Merillon N, Marcheteau E, Quillien V, Banissi C, Carpentier A, Sandoval F, Nizard M, Quintin-Colonna F, Kroemer G, Fridman WH, Zitvogel L, Oudard S and Tartour E. Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. *Oncoimmunology* 2012.1:326-333.

Autres articles (articles publiés dans des revues professionnelles ou techniques, etc.)

1. Von Gunten S, Shoenfeld Y, Blank M, Branch DR, Vassilev T, Käsermann F, Bayry J, Kaveri SV, Simon HU. IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist. *Nature Rev Immunol*. 2014. 14: 349.
2. Bayry J. Journals: Open-access boom in developing nations. *Nature* 2013.497:40.
3. Bayry J. Government: More credit due to India's scientists. *Nature* 2012. 484:167.

2. Ouvrages

Monographies et ouvrages scientifiques, éditions critiques, traductions

sans objet

Direction / édition scientifique

1. 2014. Editor (J Bayry), 'The TNF superfamily: Methods and Protocols', Book series 'Methods in Molecular Biology'. Humana Press, USA (Springer publishing group). <http://link.springer.com/book/10.1007/978-1-4939-0669-7>
2. 2017. Editors (J Bayry and SV Kaveri), 'Natural antibodies: Methods and Protocols', Book series 'Methods in Molecular Biology'. Springer publishing group. <http://www.springer.com/us/book/9781493971794>
3. 2017. Editor of a book (J Bayry), 'Emerging and re-emerging infectious diseases of livestock'. Springer publishing group. <http://www.springer.com/us/book/9783319474243>

Chapitres d'ouvrage

1. Lecerf M, Jarossay A, Kaveri SV, Lacroix-Desmazes S, and Dimitrov JD. Methods for Post-Translational Induction of Polyreactivity of Antibodies. *Methods Mol Biol*. 2017 (in press, ISBN 978-1-4939-7179-4).
2. Davies MN, Pere H, Bosschem I, Haesebrouck F, Flahou B, Tartour E, Flower DR, Tough DF, and Bayry J. In Silico Adjuvant Design and Validation. *Methods Mol Biol*. 2017. 1494: 107-125.
3. Saha C, Stephen-Victor E, Friboulet A, Bayry J, Kaveri SV. Viscum album and its anti-inflammatory effect: Angle of cytokine induced selective inhibition of COX2. In *Die Mistel in der Tumorthherapie 4* (Edited by Scheer R, Alban S, Becker H, Beer AM, Blaschek W, Kreis W, Matthes H, Schilcher H, Spahn G and Stange R). 2016. Page:196-203.

4. Elluru SR, Kaveri SV, and Bayry J. Regulation of human dendritic cell functions by natural anti-CD40 antibodies. *Methods Mol Biol.* 2014. 1155: 47-54.
5. Patil V, Bayry J, Lacroix-desmazes S, Kazatchkine MD and Kaveri SV. Autoantibodies in therapeutic preparations of human intravenous immunoglobulin (IVIG). *Autoantibodies 3rd Edition (Shoenfeld Y, Meroni PL and Gershwin E, Editors) Elsevier Publisher, Waltham/Oxford.* 2014. Page: 305-310.

3. Colloques / congrès, séminaires de recherche

Éditions d'actes de colloques / congrès

sans objet

Articles publiés dans des actes de colloques / congrès

1. Lacroix-Desmazes S, Scott DW, Goudemand J, Van Den Berg M, Makris M, Van Velzen AS, Santagostino E, Lillicrap D, Rosendaal FR, Hilger A, Sauna ZE, Oldenburg J, Mantovani L, Mancuso ME, Kessler C, Hay CR, Knoebl P, Di Minno G, Hoots K, Bok A, Brooker M, Buoso E, Mannucci PM, Peyvandi F. Summary report of the First International Conference on inhibitors in haemophilia A. *Blood Transfus.* 2017. doi: 10.2450/2016.0252-16. (Epub ahead of print)
2. Galeotti C, Stephen-Victor E, Sharma M, kaveri SV, Bayry J. Orientation of the immune response by basophils. *Rev Fr Allergol.* 2016. 56:117-119. (11th Congrès Francophone d'Allergologie, Paris, France, April 19-22, 2016)
3. Dargaud Y, Pavlova A, Lacroix-Desmazes S, Fischer K, Soucie M, Claeysens S, Scott DW, d'Oiron R, Lavigne-Lissalde G, Kenet G, Escuriola Ettingshausen C, Borel-Derlon A, Lambert T, Pasta G, Négrier C. Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014. *Haemophilia* 2016. 22 Suppl 1:1-24.
4. Kaveri SV, Lecerf M, Saha C, Kazatchkine MD, Lacroix-Desmazes S, Bayry J. Intravenous immunoglobulin and immune response. *Clin Exp Immunol.* 2014. 178: 94-96. (7th International Immunoglobulin Symposium, Interlaken, Switzerland, April 3-5, 2014)
5. Bayry J and Radstake TR. Immune-mediated inflammatory diseases: progress in molecular pathogenesis and therapeutic strategies. *Expert Rev Clin Immunol.* 2013. 9:297-299. (7th European workshop on immune-mediated inflammatory diseases, Noordwijk aan Zee, The Netherlands November 28-30, 2012)

Autres produits présentés dans des colloques / congrès et des séminaires de recherche

sans objet

4. Développements instrumentaux et méthodologiques

Prototypes et démonstrateurs

sans objet

Plateformes et observatoires

sans objet

5. Produits et outils informatiques

Logiciels

sans objet

Bases de données / cohortes

Constitution of a retrospective database of patients with severe hemophilia A in the frame of the FP7 IMI Abirisk project (Work packages 1 and 4).

Corpus

sans objet

Outils présentés dans le cadre de compétitions de solveurs

sans objet

Outils d'aide à la décision

sans objet

6. Brevets, licences et déclarations d'invention

- 2017 15 février 2017. Lacroix-Desmazes S, Mondoulet L, Dioszeghy V. "Method of treating haemophilia by inducing tolerance to blood factors". EP20130306453 20131022 ; WO2014EP72508 20141021
- 2017 16 mars 2017. R Mallone, S Lacroix-Desmazes. Prenatal therapy to induce immune tolerance. US201615190272 20160623.
- 2016 13 July 2016. R Mallone, S Lacroix-Desmazes, N Gupta, S Culina. "Methods and pharmaceutical compositions for inducing immune tolerance by mucosal vaccination with Fc-coupled antigens". WO/2017/012959. PCT/EP2016/066690
- 2015 12 une 2015. Carl-Wilhelm Vogel, Paul Finnegan, Julie Rayes, Sébastien Lacroix-Desmazes. Method for prevention of immunogenicity related to biologics therapy. PCT/US2015/035693
- 2014 18 décembre 2014. S Lacroix-Desmazes, JD Dimitrov, C Planchais, SV Kaveri. "Method for obtaining a population of regulatory B cells". WO2014198717 (A1). EP20130305783 20130611

7. Rapports d'expertises techniques, produits des instances de normalisation

- 1 Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, de Wit TD, Eichinger S, Fibbe W, Green T, de Haas F, Iolascon A1, Jaffredo T, Rodeghiero F, Salles G, Schuringa JJ; the other authors of the EHA Roadmap for European Hematology Research (André , Kaveri SV, Lacroix-Desmazes S, Bayry J, Zieger B). The European Hematology Association Roadmap for European Hematology Research: a consensus document. *Haematologica*. 2016;101:115-208.
- 2 Dimichele DM, Lacroix-Desmazes S, Peyvandi F, Srivastava A, Rosendaal FR; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders. Design of clinical trials for new products in hemophilia: communication from the SSC of the ISTH. *J Thromb Haemost*. 2015. 13:876-879.
- 3 Rup B, Pallardy M, Sikkema D, Albert T, Allez M, Broet P, Carini C, Creeke P, Davidson J, De Vries N, Finco D, Fogdell-Hahn A, Havrdova E, Hincelin-Mery A, C Holland M, H Jensen PE, Jury EC, Kirby H, Kramer D, Lacroix-Desmazes S, Legrand J, Maggi E, Maillère B, Mariette X, Mauri C, Mikol V, Mulleman D, Oldenburg J, Păntău G, R Pedersen C, Ruperto N, Seitz R, Spindeldreher S, Deisenhammer F; ABIRISK Consortium. Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium. *Clin Exp Immunol*. 2015. 181:385-400.

8. Produits des activités didactiques

Ouvrages
sans objet

E-learning, moocs, cours multimedia, etc.
sans objet

9. Produits destinés au grand public

Émissions radio, TV, presse écrite

- 2015 le quotidien du médecin, 22 février 2015, Mieux que faire disparaître les inhibiteurs, prévenir leur survenue L'hémophilie A pourrait bientôt bénéficier d'une tolérance immunitaire in utero, by Irène Drogou
- 2015 New Scientist, 26 February 2015, Treating inherited disease could start in the womb, by Jessica Hamzelou
- 2015 Atlantico, 4 mars 2015, Les fantastiques promesses de la médecine foetale : maladies génétiques, hémophilie, allergies, demain les traitements commenceront avant même la naissance
- 2015 CNRS - sciences du vivant, <http://www.cnrs.fr/insb/recherche/parutions/articles2015/s-lac...> 6 mars 2015, Un cheval de Troie pour rendre le fœtus hémophile A tolérant au facteur VIII thérapeutique
- 2015 <http://www.inserm.fr/actualites/rubriques/actualites-recherche...> 6 mars 2015, Hémophilie A : induire une tolérance précoce au facteur VIII pour empêcher les complications
- 2013 DBV technologies, 22 octobre 2013, communiqué de presse: DBV Technologies et l'Inserm signent un accord de collaboration de recherche visant à développer une nouvelle application de la technologie Viaskin® afin de traiter les patients hémophiles A réfractaires au facteur VIII

Produits de vulgarisation : articles, interviews, éditions, vidéos, etc.

- 2012 Le Figaro, 27 août 2012, dossier Santé, L'hémophilie de mieux en mieux prise en charge: vers des traitements plus efficaces et plus adaptés, by Martine Lochouarn

2012-2013 8 general articles for *Veterinary Literature World*

Produits de médiation scientifique
sans objet

Débats science et société

- 2013 Intervention: Lacroix-Desmazes, S. L'hémophilie, une maladie hémorragique héréditaire. Journée Mondiale de l'hémophilie 2013, Paris, France.
- 2016 La recherche dans le domaine des maladies hémorragiques rares Les pistes prometteuses. 44e congrès de l'association française des hémophiles, Paris.

10. Autres produits propres à une discipline

Créations artistiques théorisées

- 2014 1er Prix du Concours Photo INSERM "La recherche dans la focale" dans la catégorie "L'objet scientifique détourné"**

Mises en scènes
sans objet

Films
sans objet

II. ACTIVITÉS DE RECHERCHE ET INDICES DE RECONNAISSANCE

1. Activités éditoriales

Participation à des comités éditoriaux (revues, collections)

ASSOCIATE Editor (J BAYRY)

- 1 Scientific Reports (2012-ongoing): Nature Publishing Group: Impact Factor: 5.228.
<http://www.nature.com/srep/eap-ebm/index.html#immunology>
- 2 Frontiers in Immunology (2015- ongoing): Frontiers Publisher: Associate Editor- Molecular Innate Immunity. Impact Factor: 5.695 <http://journal.frontiersin.org/journal/immunology#editorial-board>
3. PLOS ONE (2011- ongoing): Public Library Science Publisher: Impact Factor: 3.059.
<http://www.plosone.org/static/edboard.action>
6. Mediators of Inflammation (2015- ongoing): Hindawi Publisher: Impact Factor: 3.418.
7. <http://www.hindawi.com/journals/mi/editors/>
5. VirusDisease (2011- ongoing): Springer Publisher: <http://www.springer.com/life+sciences>

Editorial Board Member (J BAYRY)

1. Cellular & Molecular Immunology (2010- ongoing): Nature Publishing Group: Impact Factor: 5.193.
<http://www.nature.com/cmi/about/index.html>
2. Clinical and Vaccine Immunology (2014-19): American Society for Microbiology (ASM) Publisher: Impact Factor: 2.277. <http://cvi.asm.org/site/misc/edboard.xhtml>
3. Immunotherapy (2012-): Future Medicine Publisher: Impact Factor: 2.083.
<http://www.futuremedicine.com/page/journal/imt/editors.jsp>

Direction de collections et de séries

- 1 Editor of a special issue (J BAYRY): 'Indian J Virol' Vol 24(3), 2013, Pages 291-408 on 'Emerging viral diseases of livestock in the developing world'. <http://link.springer.com/journal/13337/24/3/page/1>

2. Activités d'évaluation

Responsabilités au sein d'instances d'évaluation

SLD

- | | |
|------|---|
| 2017 | Evaluation de 1 défense de mi-thèse |
| 2016 | Evaluation de 2 défenses de mi-thèse |
| 2015 | Evaluation de 1 défense de M2 parcours I2P UPMC et 1 défense de thèse de doctorat |
| 2014 | Evaluation de 1 défense de thèse de doctorat et de 2 mi-thèse |
| 2013 | Evaluation des dossiers d'attribution d'allocations doctorales UPMC |
| 2012 | Evaluation de 5 défenses de thèse de doctorat |

2012-2015 Responsable de la commission des thèses de l'école doctorale 394, physiologie et physiopathologie (Université Pierre et Marie Curie, Paris 6)

JB	
2017	Evaluation de 1 défense de thèse de doctorat
2016	Evaluation de 2 défenses de thèse de doctorat et 1 défense de HDR
2015	Evaluation de 2 défenses de thèse de doctorat et 1 défense de HDR
2013	Evaluation de 1 mi-thèse
2012	Evaluation de 1 défense de thèse de doctorat
JDD	
2016	Evaluation de 1 défense de thèse de doctorat
2016	Evaluation de 1 défense de mi-thèse de doctorat
2015	Evaluation de 1 défense de thèse de doctorat

Évaluation d'articles et d'ouvrages scientifiques

SLD	British Journal of Haematology, BloodReviews, Blood, Haemophilia, PlosOne, Journal of thrombosis and haemostasis, Clinical immunology, Thrombosis and Haemostasis, J Immunol, Haemophilia
JB	Sci Transl Med, Nature Commun, Nature Rev Rheumatol, Arthritis & Rheumatol, Plos Pathog, Trends Immunol, Cancer Res, Ann Rheum Dis, Mucosal Immunol, J Infect Dis, Oncoimmunology, Frontiers Immunol, Int J Cancer, Mol Oncology, J Virol, Oncotarget, mBio, PLoS One, Vaccine, Cell Mol Immunol, Retrovirology, Medicine, Cancer Immunology, Immunotherapy, Hum Immunol, J Clin Immunol, Clin Vaccine Immunol, Innate Immunity, Cytokine, Immunol lett, Cell Immunol
JDD	Molecular Immunology, Blood, PLoS ONE, BBA - General Subjects, Protein Science, Chemical Biology, Immunology Letters, Scientific Reports, Genes and Immunity, Journal of Molecular Recognition, Redox Reports, British Journal of Haematology and Journal of Biological Research.

Évaluation de laboratoires (type Hceres)

sans objet

Évaluation de projets de recherche

SLD	
2012	Prix Henri Chaignaux, Allocations de recherche en thèse de doctorat (GFRS)
2014	Téléthon italien, AOI GCS MERRI Montpellier-Nimes 2014 'recherche clinique jeune chercheur', Programme de coopération ECOS Sud-CONICYT (Chili) Programme de coopération ECOS Sud-CONICYT (Chili)
2016	Wetenschappelijk Fonds Willy Gepts (WFWG, Belgium), Association française des Hémophiles (AFH), Téléthon italien
JB	
2016-	Member of European Research Council (ERC): Panel Member of a Consolidator Grant Panel "Immunity and Infection" LS6
2015	Scientific Council Member: INNO INDIGO partnership Programme on "Diagnostic and interventions in chronic non-communicable diseases": Innovation-driven initiative for the development and integration of Indian and European research (India and Belgium, Estonia, France, Germany, Norway, Portugal)
2015	Scientific projects of Italian Ministry of Health, Italy
2014	Dutch Arthritis association, Netherlands

3. Activités d'expertise scientifique

Activités de consultant

SLD	
2017	Advisory board for Bayer, Paris, France
2016-	Consultant for DBV technologies, Bagneux, France
2016	Advisory board for SOBI, Paris, France
2015	Advisory board for Baxalta, Paris, France

Participation à des instances d'expertises (type Anses) ou de normalisation

SLD	
2011-2013	Project Group on Clinical Trials for New Products in Hemophilia: FVIII/IX Subcommittee of the Scientific and Standardization Committee (SSC) of the International Society on Thrombosis and Haemostasis

Expertise juridique

sans objet

4. Organisation de colloques / congrès

2012 J BAYRY: International Scientific Committee Member for 7th European workshop on immune-mediated inflammatory diseases, Noordwijk aan Zee, November 28-30, The Netherlands

5. Post-doctorants et chercheurs accueillis

Post-doctoral fellows

2015-	Maud Teyssandier	FP7-IMI-ABIRISK	1 article et 1 revue
2014-2016	Varun Kumar Sharma	INSERM-LIA post-doc fellowship Devenir: Assistant Professor at Noida International University, India	3 articles et 1 revue
2011-2015	Julie Rayes	ANR AcCatPat ANR-09-GENO-028 Devenir: Associated professor, University of Birmingham, UK	2 articles et 1 revue
2011-2015	Nimesh Gupta	ANR-10-Blanc SVSE 3, ANR-10-BLAN-1118 Devenir: PI at the Indian Institute of Immunology, New Delhi, India	8 articles, 2 revues
2012-13	Veerupaxa Gouda Patil (Campus France)	Devenir: Augusta University, GA, USA	1 article et 1 revue

Scientists hosted in the team

2016 Nina Bozinovic, University of Belgrade, Faculty of Chemistry, Belgrade, Serbia (October 2016)
 2016 KN Balaji (IISc, India) (CEFIPRA collaboration)
 2015 Vandana Pradhan (NIHH, India) (Under LIA program)
 2014 KN Balaji (IISc, India) (CEFIPRA collaboration)
 2013 Tchavdar Vassilev, Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria
 2013 Manjunatha Reddy (NIVEDI, India)
 2013 Sahana Holla (IISc, India) (CEFIPRA collaboration)
 2013 Vandana Pradhan (NIHH, India) (Under LIA program)
 2012 Fernando Canale (National University of Cordoba, Argentina)
 2012 Marcos Munoz (National University of Cordoba, Argentina)
 2012 Prathap Kothapalli (Veterinary Colleague, Bangalore, India)

6. Interactions avec les acteurs socio-économiques

Contrats de R&D avec des industriels

2016-2018 LFB Biomedicaments: «Exploring the role of IVIG on macrophage polarization » 35.000 € HT
 2016-2018 Pfizer Aspire Haemophilia research award 2016. « Adjuvant effect of complement activation on the immune response to therapeutic factor VIII ». 60,000 € HT
 2016-2018 Novonordisk Investigator Sponsored Study (ISS) « Levels of vitamin D as a risk factor for the development of FVIII inhibitors in preclinical models of hemophilia A ». 41600 €HT
 2015-2018 CSL Behring, Switzerland. «Immunoregulatory role of IVIg and monomeric IgA on human basophils and Th17 ». 45 000 €/year HT
 2015-2016 Contrat Minapharm. « Half-life and immunogenicity of Neureight as compared to Advate » 29.120 € HT.
 2014-2016 Pfizer Aspire Haemophilia research award 2014. « Control of B-cell responses using btk antagonists in hemophilia A ». 60,000 € HT
 2013-2014 CSL-Behring, France. « Etude rétrospective de la valeur prédictive de l'affinité des peptides issus du facteur VIII thérapeutique sur l'apparition d'anticorps inhibiteurs du FVIII chez les patients atteints d'hémophilie A avec mutation faux-sens ». 15000 €HT
 2013-2014 DBV Technologies, France. « Induction of tolerance to exogenous FVIII upon epicutaneous immunotherapy using Viaskin® ». 18000 € HT
 2013 CSL-Behring, France. «Changes in the T cell subsets in autoimmune patients following IVIG therapy» 20.000€, HT
 2012-2016 Grifols USA. « Importance of VWF for the immunogenicity of FVIII ». 56.000 €HT
 2012 CSL Behring, Switzerland. «Anti-inflammatory effects of sialylated Fc fragment of IVIg: In Vitro and In vivo Studies» 30.000 € HT

Bourses Cifre

sans objet

Créations de laboratoires communs avec une / des entreprise(s)

sans objet

Création de réseaux ou d'unités mixtes technologiques

sans objet

Créations d'entreprises, de start-up

sans objet

7. Contrats de recherche financés par des institutions publiques ou caritatives

Contrats européens (ERC, H2020, etc.) et internationaux (NSF, JSPS, NIH, Banque mondiale, FAO , etc.)

- 2016-2021 ERC Starting Grant. "Cofactor binding antibodies - basic aspects and therapeutic innovations". 1.255.000 € HT
- 2013 Cefipra/INSERM. « Host-Virus Interactions and Antibody Therapy for Japanese Encephalitis ». 126.000 €HT
- 2011 IMI FP7-2012-2017 IMI JU Grant agreement 115303. « Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk » 300.000 €HT
- 2017 Cefipra/INSERM. « Cost-effective strategy for the induction of immune tolerance to therapeutic factor VIII in hemophilia A ». 69.000 € HT
- 2010-2014 FP7-HEALTH-2010-260338-ALLFUN. Theme: Fungi in the **setting of inflammation, allergy and autoimmune diseases: Translating basic science into clinical practices.** 268.000 € HT
- 2012-2016 CEFIPRA. Theme: Molecular mechanisms of immune evasion by M. tuberculosis. 105.000 € HT

Contrats nationaux (ANR, PHRC, FUI, INCA, etc.)

- 2015 Financement INSERM-TRANSFERT « Preuve de concept ». « Mut-FVIII ». 15.000 € HT pour 6 mois
- 2013-2016 ANR-JCJC Cofactor-binding immunoglobulins - mechanism and physiological relevance. 150.000 € HT
- 2011-2016 International Associated Laboratory (INSERM, France-ICMR, India). Theme: Immunopathology and therapeutic immunointervention in immunohematological diseases” (IMPACT) 25.000 € HT (and post-doc salary for 1 year 3 months)
- 2010-2014 ANR-10-BLAN-1309. Theme: Hydrophobin of airborne fungal spores: structural analysis and immune response 158.248 € HT

Contrats avec les collectivités territoriales

sans objet

Contrats financés dans le cadre du PIA

sans objet

Contrats financés par des associations caritatives et des fondations (ARC, FMR, FRM, etc.)

- 2016 CoMETH-Recherche 2016. « Prediction de l’alloimmunisation contre le facteur de Willebrand thérapeutique chez les patients atteints de maladies de Willebrand de type 3 ». 15.000 € HT
- 2015 Financement Fondation maladies rares/Phenomin. 2ème appel à projets ‘Mouse models and rare diseases’. « Generation of a novel mouse model of hemophilia A constituted of mice transgenic for a human T cell receptor specific for therapeutic factor VIII ». 17000 € HT
- 2015-2017 Fondation pour la Recherche Médicale: 120 000€: Thesis fellowship to Caroline Galeotti. Theme: Rôle immunorégulateur des thérapeutique immunoglobulines intraveineuses sur les basophiles humains et application potentielle au traitement des dermatomyosites.

8. Indices de reconnaissance

Prix

- 2016 Prix Martin Villar Award - Grifols (Nimesh Gupta)
- 2016 J BAYRY : ‘Sentinels of Science’ Award by Publons (<https://publons.com/>)
- 2015 Prix Martin Villar Award - Grifols (Yohann Repessé, Ivan Peyron)
- 2015 J BAYRY : Most Prolific Reviewer Award (April-July 2015) and Top Reviewer from France (April-July 2015) Award by Publons (<https://publons.com/>) <https://publons.com/about/rewards/>
- 2014-2017 J BAYRY : Excellency Award for Research and Mentoring Doctoral Students (PEDR) by INSERM
- 2010-2013 J BAYRY : Scientific Excellency Award (PES) by INSERM

Distinctions

- 2016-now J BAYRY : Nomination for the European Research Council (ERC): Panel Member of a Consolidator Grant Panel LS6 “Immunity and Infection”
- 2015 J BAYRY : Nomination as Scientific Council Member for European Union INNO INDIGO research program
- 2016-18 J BAYRY : Fellowship of Academy of Translational Medicine Professionals FACadTM (European Society for Translational Medicine) Vienna, Austria

Séjours dans des laboratoires étrangers

SLD

- 2016 1 week at the Indian Institute of Immunology, New-Delhi, India
 2015-2017 18 months at the University of Oxford, Ludwig Institute for Cancer Research. John Christianson's lab
SVK
 2015-2019: CNRS bureau, French Embassy, New Delhi, India.
JB
 2015, 2013, 2012: 15 days each at the Indian Institute of Science (Bangalore, India) under CEFIPRA project

Responsabilités dans des sociétés savantes

- 2013 SLD: Membre consultant du conseil scientifique de l'Association Française des Hémophiles

Invitations à des colloques / congrès à l'étranger, séjours dans des laboratoires étrangers

SLD

- 2012 Immunoprotective effect of VWF towards therapeutic FVIII. In XXVI. Biotest Hemophilia Forum, Seefeld (Austria).
 2012 Immunoprotective effect of VWF towards therapeutic FVIII in experimental haemophilia A. In Association pour la Thrombose et l'hémostase pédiatriques, Lille, France.
 2012 VWF and immunogenicity of FVIII. In Grifols - Investigator sponsored Research forum, Raleigh (Etats-Unis).
 2012 The immunology of FVIII inhibitors. In Octapharma Academy - Coagulation disorder, Vilnius (Lituanie).
 2012 The Immunology of FVIII inhibitors. In Octapharma Academy - Modern management of VWD and haemophilia, Kiev (Ukraine).
 2012 Virtual reality of catalytic antibodies. In Second International Workshop on Natural Antibodies, Bern, Switzerland.
 2013 Immunogenicity of novel products and its evaluation. In International Society on Thrombosis and Haemostasis (ISTH) - SSC subcommittee, Amsterdam (The Netherland).
 2013 Is there a role for von Willebrand factor in ITI outcome for inhibitor-positive hemophilia A patients ? In 58. Jahrestagung der Gesellschaft für Thrombose- un Hämostaseforschung (GTH), Vienne (Autriche).
 2013 Results of pre-clinical studies with VWF. In CSL Behring Symposium, Melbourne (Australie).
 2013 The role of von Willebrand factor in regulating factor VIII immunogenicity In IV Biotest European Haemophilia Forum, Budapest (Hongrie).
 2013 Induction of FVIII-specific tolerance in hemophilia A upon transfer of Fc-fusion FVIII via the materno-foetal interface. In International Autoimmunity Congress, Nice, France.
 2014 Allo-immunisation to therapeutic botulinum neurotoxin serotype A. In Ipsen Workshop, Chantilly
 2014 Propriétés inattendues des anticorps. In Les interactions moléculaires en biologie - Méthodes d'étude et ciblage thérapeutique, Cap Hornu (France).
 2014 ObsITI: Immuno-monitoring of hemophilia A patients under ITI. In Octapharma symposium, Melbourne (Australie).
 2014 Les recherches sur les inhibiteurs. In Reunion de réflexion sur les projets de recherche à soutenir par l'association française des hémophiles, Paris (France).
 2014 Catalytic antibodies in auto and alloimmunity. In 15th Beaune Seminar in Transplant Research, Beaune (France).
 2014 FVIII immunogenicity: the role of VWF. In 5th International Coagulation Meeting: The evolving role and future relevance of plasma-derived therapies in the management of bleeding disorders, Barcelone (Espagne).
 2015 Overview of FVIII immunogenicity by highlighting the particularities of FVIII. In 7th Open scientific EIP Symposium on immunogenicity of Biopharmaceuticals Lisbonne (Portugal).
 2015 Potenziale immunogenico del F VIII. In il fattore FVIII ricombinante da linea cellulare umana, Barga (Italie).
 2015 Does VW alter the immune system? In VW disease and where we are today, Londres (Royaume-Uni).
 2016 FcRn and prevention of inhibitor development in hemophilia. In Congrès du Groupe Français d'études sur l'Hémostase et la Thrombose Et Coordination Médicale pour l'Etude et le Traitement des maladies Hémorragiques constitutionnelles, Tours.
 2016 The immune response to therapeutic FVIII. In 1st European Congress on Thrombosis and Haemostasis, The Hague (Pays-Bas).
 2016 Alloantibodies and autoantibodies. In 2016 International Conference on Inhibitors in Hemophilia A, Milan (Italie).
 2016 La recherche dans le domaine des maladies hémorragiques rares Les pistes prometteuses. In 44e congrès de l'association française des hémophiles, Paris.
 2016 Cellular Models of Immunogenicity. In 62nd Annual SSC Meeting of the ISTH, Montpellier.
 2016 Regulatory T cells in hemophilia A. In 9th annual congress of the European Association for Haemophilia and Allied Disorders, Malmö (Suède).
 2016. Epicutaneous immunotherapy using factor VIII reduces the inhibitory immune response to therapeutic factor VIII in experimental hemophilia A. In AAAAI 2016 Annual Meeting, Los Angeles (Etats-Unis).
 2017 The protective role of VWF against FVIII inhibitors. In Grifols GTH Symposium, Basel (Suisse).
 2017 Effect of plasma from patients with hemophilia A on the maturation of dendritic cells In ABIRISK 6th annual meeting, Florence (Italie).

JB

- 2016 Orientation of immune response by basophils. Congrès Francophone d'Allergologie 2016, Palais des Congrès, Paris, April 20, France

- 2015 Cross-talk between α -1,3-glucans of *A. fumigatus* and human dendritic cells. Fungal cell wall 2015 conference, Paris. October 26-28, , France
- 2014 Targeting regulatory T cells in vaccination. International conference on host-pathogen interactions, Hyderabad, 12-15 July, India
- 2014 Molecular mechanisms of immune evasion by *M. tuberculosis*. CEFIPRA annual meeting, Dinard, 20 May, France
- 2014 Interaction of *Aspergillus fumigatus* PAMPS with human innate cells. Fungi in the setting of inflammation, allergy and autoimmune diseases: translating basic science into clinical practices: ALLFUN 3rd European annual meeting (one talk plus chairing a session), Borgo Riccio, 13-15 April, Italy
- 2014 IVIg and Tregs: how do natural antibodies regulate the regulators? 9th International Congress on Autoimmunity, 26-30 March, Nice, France (Two talks plus chairing a session)
- 2013 Therapeutic utility of circulating immunoglobulins: lessons from intravenous immunoglobulin. 15th International congress of immunology, Satellite Meeting SM5-Fungi in the setting of inflammation, allergy and autoimmune diseases translating basic science into clinical practices, Perugia, 29-30 August, Italy
- 2012 α -1-3 glucans and human dendritic cells. Fungi in the setting of inflammation, allergy and autoimmune diseases: translating basic science into clinical practices: ALLFUN 2nd European annual meeting (plus chairing a session), Borgo Scopeto Relais, September 30-October 2, Italy
- 2012 Immunotherapy with IVIg: mechanism of Treg expansion. Fungi in the setting of inflammation, allergy and autoimmune diseases: translating basic science into clinical practices: ALLFUN 2nd European annual meeting (two talks plus chairing a session), Borgo Scopeto Relais, September 30-October 2, Italy
- 2012 Targeting regulatory T cell and dendritic cell interaction in vaccination: CCR4 antagonists as molecular adjuvants. Conference on 'Inducing and breaking tolerogenic antigen presenting cell function', The Penridge Suite, 5 July, London, UK

JDD

- 2015 Surface plasmon resonance for real-time Ag - Ab interactions. 2nd Black Sea International Immunology School (EFIS course) Bulgaria, Sofia
- 2015 Heme-induced polyspecificity of antibodies - mechanism and physiological significance. Symposium Antibody Repertoire as Biomarker, Bulgaria, Sofia
- 2015 Heme-mediated diversification of immunoglobulin specificity - mechanism and physiological significance. Institute seminar, Instituto Gulbenkian de Ciências, Oeiras, Portugal
- 2013 Effects of heme on antibodies and on other plasma proteins under hemolytic conditions. Second Jena Heme and Heme Degradation Products Symposium, Jena, Germany.
- 2012 Next generation of IVIg: where do we stend? 8th International Congress of Autoimmunity 9-13 May. Granada, Spain
- 2012 Cryptic polyspecificity of antibodies - mechanism and biological significance. 2nd Natural Antibody Workshop 15-17 March, Bern, Switzerland

SVK

- 2015 "Immune System: Friend or Foe", Shiv Nader University, May 15, 2015
- 2015 "Effect of Von Willebrand factor on the Immunogenicity of FVIII". International Society on Thrombosis and Haemostasis, ISTH Toronto, Canada June 20-25, 2015
- 2015 Grifols Symposium at SNFMI, Tours, France, 10th December 2015
- 2014 "De Behring à Hoffmann" 6eme Rencontre CSL Behring en Immunologie. 10th January 2014. Paris. Introduction of the Nobel Laureate Professor Hoffmann.
- 2014 "A review on IVIG in Autoimmune Diseases" Medinterna Meeting February 26-27, 2014, Porto, Portugal.
- 2014 Intravenous Immunoglobulin (IVIg) and immune response, "2nd Indian National Conference on PID at the Banaras Hindu University, Varanasi on the 8-9, March 2014.
- 2014 "Fc-independent mechanisms of action of IVIG" at The 7th International Immunoglobulin Conference will be held in Interlaken, Switzerland, April 4-5 2014
- 2014 Satellite Symposium on "IVIg in the treatment of CIDP" 2014 ENS-EFNS Meeting in Istanbul, 31 May-3rd June 2014.
- 2014 Intravenous immunoglobulins: mechanism of action and indications to use in clinical neuroimmunology. 4th International Conference "Advances in Clinical Neuroimmunology", Cracow, Poland, 27-28 June 2014.
- 2014 'Host-Pathogen' interaction: Research Objectives from SkolTech point of view, Moscow, August 28, 2014
- 2014 'Bulgarian National Immunology Congress, October 3, 2014
- 2014 International Conference on Autoimmunity and Transplantation (ICAT), Goa, India. 12-16 October 2014
- 2014 'Biothérapies et biodiversité', 10ème Symposium Wamine, Paris, France, 18 October 2014
- 2014 Terasaki Foundation Laboratory, Los Angeles, USA November 13, 2014
- 2014 'The 10th Annual Symposium on Primary Immunodeficiency Diseases, Newport Beach, on November 14-15, 2014.
- 2014 Third International Conference on Primary Immunodeficiency Diseases (organized by the foundation for primary immunodeficiency diseases in collaboration indian society for primary immunodeficiency) Chennai, India, Feb 21-23, 2015
- 2014 "Neurofisiologia Clinica" Conference, in Cartagena (Colombia), 12th March 2015
- 2013 Ig Vena in CIDP: Why and When? A symposium September 22, 2013, Vienna Austria
- 2013 Progress towards individualised cancer treatments, Royal Society of Medicine, 26 - 27 September 2013, London, UK
- 2013 The third International Forum on Immunoglobulin Research (IFIR), October 3-5 Miami, FL, USA

- 2013 IVIG in autoimmune and inflammatory diseases: What's new?, University of Texas at El Paso, 7th October 2013, El Paso, USA
- 2013 Mechanisms of action of IVIG in autoimmunity and inflammation, Blood and Bone Marrow Transplantation Program, Children's Hospital, 9th October 2013, Los Angeles, USA
- 2013 9th Annual symposium on PID, Newport Beach, October 12-13, 2013, Newport Beach, CA, USA
- 2013 "Catalytic antibodies: Physiopathological and therapeutic significance" in the Franco-Russian GDR Meeting "From Molecular to Cellular Events in Human Pathologies", 17-19th October 2013, Paris, France,
- 2013 Immunomodulation: a Technology Showcase presentation, India-France Technology Summit, 23-24 October, 2013. New Delhi, India
- 2013 "Systeme immunitaire : Flic ou voyou" Presentation grand publique à Buc, France, Novembre 2013
- 2012 International Conference on Nervous System Autoimmunity (NSA) Bangalore India, January 27-30,
- 2012 IVIG: The good ambassador for natural antibodies. 2nd CSL Behring Natural Antibody Workshop, "The Future of Immuno-globulin Therapy", Bern, Switzerland, March 15-17, 2012. Current thoughts on the mechanisms of action of IVIG. Special Guest Lecture. Epivax's 4th Annual Tregitope Symposium, Baltimore, USA, April 20,
- 2012 IVIG perspective in the mirror of history. The 8th International Congress on Autoimmunity, Granada, Spain, May 9-13. 2012.
- 2012 IVIG: The composition, Indications, Pharmacokinetics and Adverse Effects Brazilian Immunology Symposium, Sao Paulo, Brazil, 25th May 2012.
- 2012 50 years of Human Immunoglobulin: what has changed and new perspectives on the mechanisms of action. Effects Brazilian Immunology Symposium, Sao Paulo, Brazil, 25th May 2012.
- 2012 'Immune system: An overview'. A lecture as part of my duties as Adjunct Visiting Professor at the Institute of Bioinformatics and Applied Biotechnology. Bangalore India, 17th August 2012.
- 2012 10th Annual International Symposium on Transfusion Immunology And Related Topics: Current state of knowledge for IVIG use and mechanism, University Of Toronto, Canada, 7th-8th September 2012.
- 2012 'Immunomodulation by phytotherapeutics', International Seminar on 'Effect of Climate Change on Aquatic Ecosystem and Future Planning for Sustainable Aquaculture', University Malaysia Terengganu, Malaysia, 18th September 2012.
- 2012 'Réponse immunitaire, une liaison dangereuse entre inflammation et cancer' at the '10 years of phytotherapy and micronutrition' meeting, Saumur, France. 26-28th September 2012
- 2012 'IVig in immunodeficiencies- more than mere transfer of antibodies', a scientific event organized under the Spanish immunodeficiency Society framework, Barcelona, Spain, 28th October 2012.
- 2012 'Immunoglobulin and immune response' at the 2nd International Conference on Primary Immunodeficiency Diseases, (Organized by the Foundation for Primary Immunodeficiency Diseases [FPID], and the Indian Society for Primary Immune Deficiency Diseases (ISPID), Mumbai, India, 2nd -4th February 2013.
- 2012 11th Medinterna International Meeting, "Systemic autoimmune diseases Update" Porto, Portugal, 6th - 9th February 2013
- 2012 Immunoglobuline endovena e sottocute nelle neuropatie immunomediata: quando e come usarle. Presso Villa Gallarati Scotti, Oreno di Vimercate, Lombardy, Italy; 12 April 2013
- 2012 Annual Congress of the International Society of Blood transfusion (ISBT); Amsterdam, The Netherlands, 2-5 June 2013
- 2012 Peripheral Nerve Society meeting in Saint. Malo, France June 29-July 3, 2013
- 2012 Federation of European Biochemical Societies Congress 2013, July 6-11, 2013, Saint Petersburg, Russia